Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection.
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection.
复制标题
DOI：
10.1038/s42255-021-00407-6
复制
发表时间：
2021-06
影响因子：
20.8
通讯作者：
Fiorina, Paolo
中科院分区：
文献类型：
--
作者：
Montefusco, Laura;Ben Nasr, Moufida;D'Addio, Francesca;Loretelli, Cristian;Rossi, Antonio;Pastore, Ida;Daniele, Giuseppe;Abdelsalam, Ahmed;Maestroni, Anna;Dell'Acqua, Marco;Ippolito, Elio;Assi, Emma;Usuelli, Vera;Seelam, Andy Joe;Fiorina, Roberta Maria;Chebat, Enrica;Morpurgo, Paola;Lunati, Maria Elena;Bolla, Andrea Mario;Finzi, Giovanna;Abdi, Reza;Bonventre, Joseph V.;Rusconi, Stefano;Riva, Agostino;Corradi, Domenico;Santus, Pierachille;Nebuloni, Manuela;Folli, Franco;Zuccotti, Gian Vincenzo;Galli, Massimo;Fiorina, Paolo
据报道，COVID-19患者的高血糖症患病率更高。SARS-CoV-2感染引起的细胞因子释放可能通过影响葡萄糖稳态而加速代谢改变的发生。在这里，我们描述了没有任何糖尿病既往史或诊断的COVID-19患者的糖代谢控制、胰岛素抵抗和β细胞功能异常，并记录了疾病发作后两个月康复患者的血液学异常。在意大利因COVID-19住院的551名患者中，我们发现46%的患者血糖过高，而27%的患者血糖正常。在一部分患者中使用临床检测和连续血糖监测，我们检测到糖代谢控制改变，胰岛素抵抗和异常细胞因子谱，即使在正常血糖患者中也是如此。从COVID-19中恢复至少两个月的患者可以检测到血糖异常。我们的数据表明，COVID-19与异常的糖代谢控制相关，即使在恢复后也会持续存在，这表明有必要在长期COVID的背景下进一步研究代谢异常。
Patients with COVID-19 have been reported to have a greater prevalence of hyperglycemia. Cytokine release as a consequence of SARS-CoV-2 infection may precipitate the onset of metabolic alterations by affecting glucose homeostasis. Here we describe abnormalities in glycometabolic control, insulin resistance and β-cell function in patients with COVID-19 without any pre-existing history or diagnosis of diabetes, and document glycaemic abnormalities in recovered patients two months after onset of disease. In a cohort of 551 patients hospitalized for COVID-19 in Italy, we found 46% of patients to be hyperglycemic whereas 27% are normoglycemic. Using clinical assays and continuous glucose monitoring in a subset of patients, we detected altered glycometabolic control, with insulin resistance and an abnormal cytokine profile, even in normoglycaemic patients. Glycaemic abnormalities can be detected in patients, who recovered from COVID-19, for at least two months. Our data demonstrate that COVID-19 is associated with aberrant glycometabolic control, which can persist even after recovery, suggesting that further investigation of metabolic abnormalities in the context of Long COVID is warranted.
登录
查看更多内容
影响因子：
1.9
作者：
Astorri, E;Fiorina, P;Magnati, G
通讯作者：
Magnati, G
影响因子：
5.2
作者：
Erion K;Corkey BE
通讯作者：
Corkey BE
影响因子：
3.7
作者：
Folli, Franco;Guzzi, Valeria;Fiorina, Paolo
通讯作者：
Fiorina, Paolo
影响因子：
7.7
作者：
Krogvold, Lars;Edwin, Bjorn;Dahl-Jorgensen, Knut
通讯作者：
Dahl-Jorgensen, Knut
影响因子：
--
作者：
Fabbri, Andrea;Marchesini, Giulio;Rizzo, Stefano Giovanni
通讯作者：
Rizzo, Stefano Giovanni